The Effect of Cetirizine on Bronchoconstriction
| Status: | Recruiting |
|---|---|
| Conditions: | Allergy, Asthma, Asthma |
| Therapuetic Areas: | Otolaryngology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 6 - 20 |
| Updated: | 3/28/2019 |
| Start Date: | May 11, 2018 |
| End Date: | December 31, 2019 |
| Contact: | Stephen Blumberg, MD |
| Email: | stephen.blumberg@nychhc.org |
| Phone: | 718-918-7548 |
The Effect of Cetirizine on Bronchoconstriction in Patients With Allergic Rhinitis and Wheezing in the Pediatric Emergency Department
The purpose of this study is to determine the effect of cetirizine, an oral antihistamine, on
wheezing in patients with allergic rhinitis. Patients presenting to the pediatric emergency
department who have a history of allergic rhinitis and who are wheezing will be asked to
participate. Half of patients will receive a dose of cetirizine and the other half will
receive placebo and their response will be monitored over the course of their emergency
department visit with vital signs, physical examinations, and measurement of
bronchoconstriction with spirometry.
wheezing in patients with allergic rhinitis. Patients presenting to the pediatric emergency
department who have a history of allergic rhinitis and who are wheezing will be asked to
participate. Half of patients will receive a dose of cetirizine and the other half will
receive placebo and their response will be monitored over the course of their emergency
department visit with vital signs, physical examinations, and measurement of
bronchoconstriction with spirometry.
This is a prospective randomized, placebo-controlled trial to look at the effect of
cetirizine on bronchoconstriction in patients with allergic rhinitis who present to the
Pediatric Emergency Department with wheezing. Oral second generation antihistamines such as
cetirizine are already the standard of care for allergic rhinitis. Wheezing pediatric
patients with allergic rhinitis who are not already on this therapy will be randomized to
receive either age-appropriate-dosed cetirizine or placebo in addition to standard asthma
therapy at the discretion of the treating clinician, and will be monitored every 30 minutes
with asthma scores and FEV1 measurements. At the conclusion of 3 hours, each patient who
received placebo will receive a dose of cetirizine, and each patient who received cetirizine
will receive a placebo medication dose, such that initiating therapy for allergic rhinitis is
delayed by no more than 3 hours.
cetirizine on bronchoconstriction in patients with allergic rhinitis who present to the
Pediatric Emergency Department with wheezing. Oral second generation antihistamines such as
cetirizine are already the standard of care for allergic rhinitis. Wheezing pediatric
patients with allergic rhinitis who are not already on this therapy will be randomized to
receive either age-appropriate-dosed cetirizine or placebo in addition to standard asthma
therapy at the discretion of the treating clinician, and will be monitored every 30 minutes
with asthma scores and FEV1 measurements. At the conclusion of 3 hours, each patient who
received placebo will receive a dose of cetirizine, and each patient who received cetirizine
will receive a placebo medication dose, such that initiating therapy for allergic rhinitis is
delayed by no more than 3 hours.
Inclusion Criteria:
- History of allergic rhinitis
- Wheezing
Exclusion Criteria:
- Use of antihistamine within the past 72 hours
- Chronic Pulmonary Condition other than asthma
- Other contraindication to cetirizine
- Severe asthma exacerbation requiring resuscitation
We found this trial at
1
site
1400 Pelham Parkway South
Bronx, New York 10461
Bronx, New York 10461
(718) 918-5000
Phone: 718-918-5826
Jacobi Medical Center In 1955, the NYC Department of Hospitals opened a new, specialized care...
Click here to add this to my saved trials
